- First live demonstration of ARKE GEN2 proprietary robotic lower-body exoskeleton -
TORONTO, Jan. 27, 2016 /CNW/ -- Bionik Laboratories Corp. (OTCQX: BNKL), a pioneering medical device and robotics company with a focus in developing technologies and solutions for individuals with neurological disorders ("Bionik" or the "Company"), announced today that the Company will present at the 2016 Colloquium on Sports and People with Disabilities at l'Université de Poitiers being held February 5, 2016, in Poitiers, France.
Michal Prywata, Chief Operating Officer, will discuss the development of Bionik's primary product, ARKE™, a robotic lower-body exoskeleton device designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking and other motion. Bionik expects to report key verification and clinical data on its second generation exoskeleton, ARKE GEN2, from Canadian rehabilitation center testing in mid-2016.
"Bionik is honored to be invited to participate in this important event highlighting the latest scientific developments related to adaptive living, technology, equipment, materials, prosthetics and connected devices intended to enhance physical and motor abilities of people with disabilities," stated Mr. Prywata.
The Bionik team will present an onsite demonstration of ARKE GEN2, the first comprehensive lower body exoskeleton with tablet control. Following its clinical development and the appropriate health agency approvals, ARKE will initially be used in a rehabilitation environment, with the eventual goal of being made available for home use.
"Robotic exoskeletons like ARKE have the potential to transform the future for mobility impaired patients by significantly improving rehabilitation stimulation," added Mr. Prywata. "We purposefully reengineered ARKE for a lighter mechanical profile and significantly improved control, adaptability, safety and electronics to allow users to walk more easily and efficiently. I look forward to joining this distinguished group in France to for the first live demonstration in Europe of ARKE GEN2's capabilities."
The 2016 Colloquium on Sports and People with Disabilities, the Health of Aging People with Disabilities: Physical and Athletic Activities and Technological Innovations focuses on aging people with disabilities. The colloquium addresses a variety of healthcare topics including physical, health, educational and social issues as well as the latest technological innovations in rehabilitation, autonomy and adaptive sports. Participants include professionals in healthcare, education, social work, sports, and culture, along with athletes and other individuals with disabilities, their families, and organizations engaged expanding awareness and advancement of resources and technologies related to the support of people with disabilities.
About Bionik Laboratories
Bionik Laboratories (OTCQX: BNKL) is a pioneering medical device and robotics company with a focus in developing technologies and solutions for individuals with neurological disorders. The Bionik team has researched, developed and tested its primary product, The ARKE™, a robotic lower-body exoskeleton device that is designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking and other motion. Bionik recently successfully raised approximately US$13.1 million which enables the company to advance its development and growth strategy. For more information, please visit www.bioniklabs.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.
Logo - http://photos.prnewswire.com/prnh/20150817/258751LOGO
SOURCE Bionik Laboratories Corp.
For further information: Bionik Laboratories, Inc. Contact: Jenene Thomas, Jenene Thomas Communications, LLC, (908) 996-0239, email@example.com, http://www.bioniklabs.com